Last updated: July 26, 2026
- Case: VIVUS, Inc. v. HETERO USA, Inc., 2:16-cv-04560 (U.S. District Court, Eastern District of Pennsylvania).
- Core dispute: IVUS accused HETERO of infringing VIVUS patents tied to Qsymia (phentermine/topiramate extended-release) through an FDA ANDA route to market.
- Procedural posture (high level): The litigation is part of the Qsymia patent-liability wave triggered by ANDA filings; it proceeds under the Hatch-Waxman framework, typically using Paragraph IV theories tied to Orange Book-listed patents.
- Business impact: The case affects timing and pathway for generic Qsymia ER entry, with exposure centered on whether VIVUS’s listed patents are asserted and whether HETERO is found to infringe and the patents are held valid.
What patents were asserted in VIVUS, INC. v. HETERO USA, INC. (2:16-cv-04560)?
VIVUS brought a Hatch-Waxman infringement action tied to Qsymia’s extended-release fixed-dose combination of phentermine and topiramate. In this fact pattern, the infringement claims ordinarily track Orange Book-listed patents covering one or more of the following categories:
- Composition of matter for Qsymia or key chemical intermediates
- Formulation and/or controlled-release features of the ER technology
- Method of use (e.g., dosing regimens for obesity/weight management indications)
- Manufacturing or ER-specific process steps
What to extract from the docket (litigation-lens):
- Which patent numbers are named in the complaint and which ones survive through claim construction and summary judgment.
- Whether the asserted patents are the same as the Orange Book patents referenced in HETERO’s ANDA Paragraph IV certification.
- Which asserted claims were tied to the alleged HETERO ANDA product’s proposed label and ER release profile.
Which Qsymia patent families typically appear in ANDA litigation
Qsymia ER ANDA cases commonly revolve around patent families for:
- ER dosage form design, release kinetics, and formulation chemistry
- Fixed-dose combination boundaries between phentermine and topiramate ER
- Dose titration and patient treatment methods
- Stability/manufacturing parameters for the ER system
In a litigation summary, the key deliverable is the asserted patent list and the claim scope those patents cover. For this case, that list is found in the complaint and subsequent docket filings (especially the initial infringement contentions and claim construction orders).
What was the litigation timeline in VIVUS v. HETERO (2:16-cv-04560)?
A workable litigation timeline for a Hatch-Waxman ANDA infringement case should be segmented into:
-
Filing of the lawsuit
Triggered by HETERO’s ANDA and Paragraph IV certifications for Qsymia Orange Book patents.
-
Early procedural events
- Appointment of a schedule for claim construction
- Initial infringement contentions
- Validity and invalidity contentions
- Motions practice tied to stay, scope, and pleading sufficiency
-
Markman / claim construction phase
Claim construction drives infringement and validity outcomes in the majority of ANDA cases.
-
Summary judgment and dispositive motions
Typical targets:
- non-infringement of construed claim elements
- invalidity on anticipation/obviousness
- indefiniteness or statutory-eligibility defenses depending on patent type and post-2017 case law posture
-
Pretrial and trial (or case-ending settlement)
Many ANDA disputes resolve via:
- settlement with delayed generic launch dates
- consent judgments on design-around or non-infringement
- stipulations tied to patent expiry
Business conclusion from the timeline framework:
For generic entry planning, the critical points are the dates of:
- claim construction (and outcomes)
- dispositive rulings (if any)
- settlement or stipulated dismissal (if reached)
- any injunction or timing relief granted
What were HETERO’s defenses and how did VIVUS position infringement?
In ANDA patent cases for Qsymia ER, defenses typically fall into two buckets.
Infringement defenses
- Challenge to whether the proposed generic ER dosage form practices every limitation of the asserted claims, including ER-specific features.
- Disputes over release profile, formulation structure, and manufacturing/process-linked limitations, when claims are tied to those characteristics.
- Claim construction-based non-infringement: HETERO often argues that construed claim scope does not cover HETERO’s ANDA product.
Invalidity defenses
- Anticipation (single reference obviousness less common as primary, but frequent in combination)
- Obviousness based on combinations of prior art
- Obviousness-type attacks on formulation or method-of-use features
- Statutory defenses depending on claim type and evolving patent eligibility jurisprudence
Typical VIVUS infringement framing
- The accused ANDA product meets each construed claim element.
- The Orange Book-listed patents are asserted against the FDA product described in the ANDA.
- The generic is deemed to infringe under the ANDA “artificial infringement” framework as to the patented product.
How do Orange Book listings connect to VIVUS v. HETERO?
The case is an ANDA-triggered dispute; the Orange Book listing is the map that links:
- The patent(s) VIVUS claims cover Qsymia
- The Paragraph IV certification(s) HETERO made
- The patents that the court ultimately has jurisdiction to adjudicate in the infringement action
What matters commercially
- Whether HETERO certified non-infringement/invalidity on the most “blocking” Orange Book patents
- Whether the court held any asserted patents invalid or non-infringed, which can accelerate generic entry
- Whether a settlement set an agreed launch date tied to the latest expiring asserted patent
Did the case end in a judgment, injunction, or settlement?
For planning purposes, the case outcome must be classified into one of the standard Hatch-Waxman endpoints:
- Merits judgment for VIVUS: supports enforcement against launch; may trigger injunctive relief.
- Merits judgment for HETERO: clears a pathway for generic entry upon FDA approval and patent expiry.
- Settlement and dismissal: common; typically includes:
- stipulated dismissal after payment/side consideration (or license terms)
- launch date and/or patent carve-outs
- permitted product launch timing and labeling constraints
A litigation summary should identify which occurred, with the controlling dates and any launch-relevant terms.
What generic entry risks does VIVUS v. HETERO create for Qsymia ER competitors?
The risk profile for a Qsymia ANDA filer is tied to:
- Which patents are deemed strong by the court
- Whether the adjudicated patents are “blocking” the approval-to-market timeline
- Whether other ANDA filers are bound by settlement terms or must litigate separately
Risk levers
- If VIVUS won on key claims: higher enforcement risk and delayed entry expectations.
- If VIVUS lost or claims were found invalid: accelerated entry for all ANDA applicants not already settled.
- If settlement occurred: entry timing becomes predictable but constrained by agreed launch dates.
What is the global competitive and licensing impact of this case?
Even without a cross-border patent map, a U.S. ANDA litigation often sets a de facto licensing and enforcement posture:
- Qsymia generic applicants calibrate whether they can design around by ER formulation changes or dosing method changes.
- License discussions often anchor to whether the asserted patents are composition/formulation blocking or method-of-use blocking.
- Enforcement resources concentrate on patents that survive claim construction and dispositive rounds.
Key takeaways
- VIVUS v. HETERO (2:16-cv-04560) is a Qsymia (phentermine/topiramate ER) ANDA patent infringement dispute under Hatch-Waxman.
- The patent estate at issue is the set of Orange Book-listed Qsymia patents referenced by HETERO’s Paragraph IV certifications.
- The litigation’s commercial value is driven by the outcome classification (judgment vs settlement) and which asserted patents survived claim construction and dispositive motion practice.
- Generic launch risk for Qsymia ER hinges on whether VIVUS’s asserted formulation and/or method-of-use claims were upheld, invalidated, or resolved by settlement.
FAQs
1) What triggers a Hatch-Waxman infringement suit like VIVUS v. HETERO (2:16-cv-04560)?
An ANDA with Paragraph IV certifications against Orange Book-listed Qsymia patents, followed by a suit by the NDA holder within the statutory deadline.
2) How do claim construction results affect Qsymia ER ANDA cases?
Constructions define claim boundaries for ER dosage-form and combination limitations; they often determine infringement and invalidate findings at summary judgment.
3) What patent types most frequently block Qsymia ER generic entry?
In Qsymia-related ANDA litigation patterns: patents covering ER formulation/control-release features and/or fixed-dose combination composition claims.
4) If the case settles, what typically controls generic launch timing?
A settlement agreement usually specifies a launch date tied to expiration of certain patents or a stipulated workaround/non-infringement posture.
5) Does a decision against one ANDA applicant automatically clear other applicants?
No. It depends on the scope of the judgment and whether other applicants are subject to separate litigation or settlement terms, but invalidation of a patent can materially reduce blocking risk.
References
- U.S. District Court for the Eastern District of Pennsylvania docket, VIVUS, Inc. v. HETERO USA, Inc., 2:16-cv-04560.
